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Abstract
Objective: Kidneymarkers are some of themost frequently
used laboratory tests in patient care, and correct clinical
decision making depends upon knowledge and correct
application of biological variation (BV) data. The aim of
this study was to review available BV data and to provide
updated BV estimates for the following kidney markers in
serum and plasma; albumin, creatinine, cystatin C, chlo-
ride, potassium, sodium and urea.
Content: Relevant studies were identified from a historical
BV database as well as by systematic literature searches.
Retrieved publications were appraised by the Biological
Variation Data Critical Appraisal Checklist (BIVAC). Meta-
analyses of BIVAC compliant studies with similar design
were performed to deliver global estimates of within-sub-
ject (CVI) and between-subject (CVG) BV estimates. Out of
the 61 identified papers, three received a BIVAC grade A,
four grade B, 48 grade C, five grade D grade and one was
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not appraised as it did not report numerical BV estimates.
Most studies were identified for creatinine (n=48). BV es-
timates derived from the meta-analysis were in general
lower than previously reported estimates for all analytes
except urea. For some measurands, BV estimates may be
influenced by age or states of health, but further data are
required.
Summary: This review provides updated global BV esti-
mates for kidney related measurands. For all measurands
except for urea, these estimates were lower than previously
reported.
Outlook: For the measurands analyzed in this review,
there are sufficient well-designed studies available to
publish a trustworthy estimate of BV. However, for a
number of newly appearing kidney markers no suitable
data is available and additional studies are required.
Keywords: albumin; analytical performance specifica-
tions; biological variation; creatinine; cystatin C; electro-
lytes; kidney markers; meta-analysis; urea.
Introduction
Reduced kidney function correlates strongly with
increased morbidity and mortality, and biochemical mea-
surements have a central role in diagnosing and moni-
toring of kidney disease and the effectiveness of treatment.
Essential for interpretation of laboratory test results in
these settings is knowledge of the within-subject biological
variation (CVI) of the analytes. Furthermore, data that
characterize the CVI and between-subject biological vari-
ation (CVG) can be used e.g. for the development of
analytical performance specifications [1] for internal
quality control [2] and for external quality assurance [3, 4].
Serum creatinine and urea are used to assess patients
either at risk for kidney disease, or to monitor those having
chronic kidney disease (CKD). When reviewing whether a
change in serial measurements is potentially of clinical
significance or consistent with normal biological variation
(BV), it is important to assess the BV in a setting that is
comparable to the clinical setting, thus delivering a valid
point of reference to enable safe application of the data.
This means that if a patient has their kidney function
measured every three months, BV data based on weekly
measurements may not be applicable. Thus, for the
calculation of reference change values (RCV) [1], appro-
priate CVI estimates must be applied. The RCV also takes
into account the analytical (CVA) variation of the mea-
surement method to describe the maximum expected
change between two measurements at a predetermined
level of probability. Changes in serial results over time
exceeding the RCV greater than might be expected given
relevant estimates of CVI and CVA are likely to represent
clinical important changes in renal function.
Many other important laboratory applications of BV
data also depend upon the availability of estimates of the
components of variance that are well characterized and
are of sufficient quality and thus transferable to the
population to which the laboratory tests are to be
deployed. As a consequence, concerns have been raised
around the quality of existing BV studies and the veracity
of the published BV data estimates that were collated in
the historical BV database, last revised in 2014 [5, 6]. With
this background the European Federation of Clinical
Chemistry and Laboratory Medicine (EFLM) Working
Group on Biological Variation and the Task Group on the
Biological Database have developed the recently pub-
lished Biological Variation Data Critical Appraisal
Checklist (BIVAC) [7]. The BIVAC enables an objective
assessment of the quality of BV publications by verifying
whether all essential elements that may impact upon ve-
racity and utility of the derived BV estimates are present
[7, 8]. It thus both provides a tool to review historical data
and to assess new studies and has been applied here to
enable a systematic review process applied to measur-
ands commonly used in renal medicine.
The aims of the present study were:
– To perform a systematic literature review of BV studies
published for the following analytes used in the
diagnosis and management of kidney related disor-
ders; albumin, creatinine, cystatin C, chloride, potas-
sium, sodium and urea in serum and plasma,
– To critically appraise relevant publications on these
markers by application of the BIVAC [7].
– To review the effect of different study population
characteristics and sampling intervals on associated
BV estimates, and
– To perform a meta-analysis of BIVAC compliant
studies with comparable study design to deliver global
BV estimates for kidney related analytes
Materials and methods
The initial source material identified for review was the
historical BV database, from which relevant publications
on kidney markers were retrieved (references 7–246 in
Supplementary Table 1) [5, 6]. Furthermore, multiple
systematic literature searches were performed in PubMed,
as described in detail in [7] with cut-date Feb 7th, 2020,
identifying more than 200 additional publications on
BV, 26 of which addressing kidney markers (references
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248–483 in Supplementary Table 1). The retrieved publi-
cations are identified in this review by the article number
they have been assigned in the EFLM BV database [9]
(Supplementary. Table 1). When one study included esti-
mates for several different subpopulations, such as for
instance based on sex, age or health status, a subscript
(a, b, c etc.) was added to the article number as illustrated
in Supplementary Table 1. All publications were inde-
pendently assessed by groups of two assessors, and
separately for each measurand and/or subgroup in the
same publication. In the BIVAC, each study is appraised
with regards to 14 different quality items (QI), including
the assessment of pre-analytical procedures, the mea-
surement procedure, applied statistical methods and the
presentation of data [7]. The QI may be assigned either an
A, B, C or D score, indicating increasing non-compliance.
Based on the individual scores for each of the 14 QI, an
overall BIVAC grade is given, equal to the lowest score
given to any of the QI. When there was disagreement on
the score for any QI between the two assessors, all
involved assessors reviewed the study until consensus
was reached.
The results of the BIVAC review were registered in an
Excel-file (Microsoft), together with data on the study
population, study design characteristics and associated BV
data (see Supplementary Table 2, exemplified for cystatin
C). Confidence intervals (CI) for CVI and CVG were calcu-
lated from the available data at a 95% probability level,
using the method described by Burdick [10] and Sahai [11],
when the necessary data on the mean number of subjects
and samples and estimates of CVA were reported.
The global CVI andCVG estimateswere obtained using a
meta-analysis approach, which takes into consideration the
inverse of each study’s CI and weights based on the BIVAC
grade; i.e. for an A grade paper multiplied by 4, B grade by 2
and C grade by 1 [5]. When publications reported separate
estimates for different subgroups, these estimates were first
combined to provide a common estimate by applying the
weighted mean on the point estimates and corresponding
CIs. For the global CVI, a percentile bootstrap approach [12]
was used to indicate measures of uncertainty.
Only studies reporting BV estimates from healthy
adults (age range 18–75 years) were included in the meta-
analysis. Further exclusion criteria were applied which
included: studies in which CI could not be calculated,
sampling intervals shorter than twice per week or greater
than one month, and studies only including two samples
per subject. Additionally, papers were excluded if they had
greatly differing estimates derived from non-standard
methodologies (i.e. for albumin–electrophoretic separa-
tion, for electrolytes–dry chemistry).
Results
In total, 61 BVpublications on kidneymarkerswere included.
The highest number of published studies were identified for
creatinine (n=48) (Table 1). Overall, 259 BV estimates were
identified, when included for all analytes and the different
subgroups (Table 1). Of the 61 papers reviewed, only three
received a BIVAC A grade [13–15] (Table 1), all of which are
recent papers published according to the BIVAC. Four papers
received a B grade [16–19] and the majority, 48 papers, were
awarded a C grade. The most common reasons for C scores
were, in order of frequency, the following: failure to report
homogeneityof variances (homoscedasticity,QI 10), failure to
report the number data points used to calculate the BV esti-
mates (QI 12), and failure to report and perform appropriate
testing for outliers (QI 8). Five papers (110, 220, 270, 271, 309)
were given a D score because the time between phlebotomies
was not standardized (QI 3) or multiple analyzers were used
throughout the study (QI 4). One studywasnot appraised as it
didnot report numerical BVestimates (288). For eachanalyte,
CVI estimates from all the different subgroupswith 95%CI for
the point estimate are presented (Figures 1–6). The number of
studies available to be included in the meta-analysis ranged
from three for cystatin C to 11 for creatinine (Table 2). For
several of the measurands, in particular for creatinine, meta-
analysis derived estimates appeared slightly lower than those
reported in the historical BV database [6] (Table 2). However,
direct comparisons are difficult due to the lack ofmeasures of
uncertainty for the estimates reported in the historical data-
base. Smaller differenceswere observed for the CVG estimates
(Table 2).
Table : Overview of the number of studies identified by the sys-
temic search for each measurand with the associated BIVAC grade
and number of subgroups. The subgroups were based on age, sex,




A B C D No. of
subgroups
Albumin      
Creatinine      
Cystatin C      
Chloride      
Potassium sodium      
Urea      
Total a     
aone paper did not provide a numerical estimate andwas therefore not
appraised.
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Figure 1: CVI estimates for albumin. Confidence intervals (CI) for individual papers are shown as error bars around the CVI data point. Numbers
on the x-axis represent the reference id number in the EFLM BV database (as listed in Supplementary Table 1) and letters different subgroups.
95% CI limits for the global BV estimate are shown in green.
Figure 2: CVI estimates for creatinine. Confidence intervals (CI) for individual papers are shown as error bars around the CVI data point.
Numbers on the x-axis represent the reference id number in the EFLM BV database (as listed in Supplementary Table 1) and letters different
subgroups. 95% CI limits for the global BV estimate are shown in green.
Figure 3: CVI estimates for creatinine ranked according to sample frequency, based on studies from healthy subjects. In green the upper and
lower confidence interval for the meta-analysis derived estimate for the CVI of creatinine.
Values of x-axis are ordered according to sampling interval.
D: day, W: week; m: month.
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Figure 4: CVI estimates for cystatin C.
Confidence intervals (CI) for individual
papers are shown as error bars around the
CVI data point. Numbers on the x-axis
represent the reference id number in the
EFLM BV database (as listed in
Supplementary Table 1) and letters different
subgroups. 95% CI limits for the global BV
estimate are shown in green.
Figure 5: CVI estimates for electrolytes.
Confidence intervals (CI) for individual
papers are shown as error bars around the
CVI data point. Numbers on the x-axis
represent the reference id number in the
EFLM BV database (as listed in
Supplementary Table 1) and letters different
subgroups. 95% CI limits for the global BV
estimate are shown in green.
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Discussion
The availability of robust and contextually relevant BV
estimates is in many ways an essential requirement for
delivery and effective application of clinical laboratory
results. The BIVAC may be an important improvement in
the assessment of BV studies compared with previous ap-
proaches [20]. This is because it specifies essential criteria
to be met in reported studies to produce reliable estimates
of BV. In addition, BIVAC provides a framework that will
help those planning and performing BV studies in
the future to produce valid estimates of BV that are trans-
portable into clinical practice across populations.
Furthermore, they will be immediately suitable to be
included as a fully BIVAC compliant study in the online BV
database published by the EFLM [9].
Application of BIVAC to historical publications in-
dicates many fundamental issues that are often not
addressed. As an example, the classical method for esti-
mating components of BV put forward by Fraser and Harris
[21] required testing the raw data for outliers and variance
homogeneity prior to further analysis; many authors
studying BV appear not to have addressed this requirement.
Users may not be aware of these issues, but they are clearly
identified and simply communicatedwhenBIVAC is applied
to deliver a grading against 14 QIs that address fundamental
requirements, as is done in this systematic review. This re-
view identified only three recent BIVAC grade A papers
describing BV of analytes important in the diagnosis, man-
agement and monitoring of kidney disease. All the other
included studies were graded B, C or D because of failure to
comply with one or more of the BIVAC 14 QIs. Most of the
included studies in our review had been performed in
healthy individuals, whereas a smaller number of studies
had addressed BV in different health states and age groups,
as detailed for all analytes in the following.
Figure 6: CVI estimates for urea. Confidence
intervals (CI) for individual papers are
shown as error bars around the CVI data
point. Numbers on the x-axis represent the
reference id number in the EFLM BV
database (as listed in Supplementary
Table 1) and letters different subgroups.
95% CI limits for the global BV estimate are
shown in green.
Table : Estimates for CVI and CVG resulting from the meta-analysis of BIVAC compliant studies of similar study design, accompanied by the
estimates reported in the historical BV database.
Analyte No of studies included
in meta-analysis
Meta-analysis based estimates Historical BV
database
CVI (% CI) CVG (% CI) CVI CVG
Albumin  . (.–.) . (.–.) . .
Chloride  . (.–.) . (.–.) . .
Creatinine  . (.–.) . (.–.) . .
Cystatin C  . (.–.) . (.–.) . .
Potassium  . (.–.) . (.–.) . .
Sodium  . (.–.) . (.–.) . .
Urea  . (.–.) . (.–.) . .
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Albumin
Most studies had analysed albumin in serum. Only the
recently published European Biological Variation Study
(EuBIVAS) paper received a BIVAC grade A [15]. Paper 53
was excluded from the meta-analysis because it was
visually a clear outlier, possibly related to the use of a
different measurement method (electrophoretic separa-
tion). Most other studies had applied either an immuno-
assay, or bromcresol green/purple method.
Four studies performed in non-healthy individuals
were identified, including the following disease groups:
chronic liver disease, diabetes mellitus, myocardial
infarction and renal disease. The CVI estimates derived
from these non-healthy populations did not differ signifi-
cantly from those reported in healthy subjects.
There are insufficient data to draw any conclusions on
whether age influences estimates of CVI for albumin. How-
ever, based on one study (paper 246, with a BIVAC grade C)
estimates derived from elderly participants (80–92 years)
were slightly higher, with CVI estimates of 4.0, 95% CI (3.9–
4.8) in males and 4.5% (4.1–5.0) in females, as compared to
3.4% (3.1–3.8) and 3% (2.7–3.4) in healthy adults.
Only one study performed in children was identified
(paper 248a), which reported a CVI estimates of 2.3% in a
one-day studywith samples taken every 2.5 h. However, this
represents within-day BV variation, and results may be
different in pediatric studies with longer sampling intervals.
Creatinine
The majority of studies had performed analysis of creati-
nine in serum (n=48 out of 61 papers). A comparison with
studies in plasma was not possible, because all studies in
plasma were excluded from the meta-analysis for reasons
such as using only two samples per subject, having a study
duration of only one day or studying non-healthy subjects.
The only A paper (number 333), delivering BV esti-
mates for male and female subgroups assessed with two
different analytical methods, reported some of the lowest
CVI values and the narrowest CI [13]. This A-paper is the
EuBIVAS, set up by the ELFM Working Group on BV, in
which 91 subjects were included and a strict protocol was
followed throughout. Due to the narrow CI and the high
weight given due to the BIVAC grade, this paper, reporting
a CVI of 4.2% for males and 4.6% for females, has a large
influence on the global CVI estimate (4.5%) provided by the
meta-analysis, which is lower than the previously often
used estimate of 5.9% derived from the historical BV
database. Some B papers and many of the C papers in
healthy subjects reported similar or lower CVI values
compared to this A paper; however, the associated CIs are
much wider, reflecting the smaller scale study design of
these papers, and thus they have less weight on the meta-
analysis result (Figure 2).
Regarding the analytical method for creatinine testing,
themajority of papers applied alkalinepicratemethods, and
only five papers used the enzymatic method which is
considered to be the state of the art for creatinine testing [22,
23]. There appears, however, tobenodifferencebetweenCVI
estimates delivered by the two different methods, as exem-
plified by the EuBIVAS, where BV estimates based on both
methods were derived from the same study [14]. Further-
more, six studies performed after the 2009 global restan-
dardisation of creatinine (NIST SRM 967a) were included in
themeta-analysis. Because the restandardisation resulted in
generally lower creatinine results, BV estimates reported
from post-standardisation studies could theoretically be
higher than those from pre-standardisation studies. How-
ever, no such effects were observed. Excluding the studies
performed pre-standardisation did not lead to different BV
estimates and meta-analyses performed separately for pre-
and post-standardisation studies produced similar BV esti-
mates with overlapping CIs.
Creatinine production is related to muscle mass which
changes with age and exercise and theoretically this might
impact BV within stratified groups. Two of the reviewed
studies delivered BV estimates from children (248a,
270a,b), however, in both within-day BV estimates were
reported. Three papers reported studies of elderly subjects
(over 75 years old) (papers number 49, 246 and 263). These
CVI estimates (4.3% (paper 49), 3.8% (paper 246) and 7.1%
formen; 7.0% forwomen (paper 263), respectively), appear
not to differ significantly from non-elderly, but equality is
yet to be proven.
Creatinine is the analyte that has been studied themost
in non-healthy populations (Tables 1 and 2). Given that
creatinine ismost often used tomonitor disease, the impact
of different pathologies and interventions on BV, such as
renal disease, renal post-transplant patients, diabetes
mellitus and myocardial infarction is of importance. Some
of these disease states appear to have a very distinct effect,
for example paper 7 (BIVAC grade C), whichwas performed
in renal post-transplant patients, reported a high CVI, as
does paper 45 (BIVAC grade C), which studied BV in pa-
tients with myocardial infarction. However, it is unclear if
the patients in these studies were in a stable condition, or
how to adequately define a stable condition for these
groups of patients.
Many factors, such as sampling intervals, may
impact BV estimates. This is important to take into
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consideration as creatinine may be measured several
times per day for hospitalized patients and less
frequently for patients being monitored for CKD pro-
gression (e.g. every three months) [22]. Figure 3 illustrates
that based on the studies identified in our review, there
are no apparent differences in CVI values between shorter
(once per week or less) and longer (once per month or
more) sampling intervals.
Cystatin C
Only three papers (203, 221 and 483) out of the 11 identified
studies on cystatin C could be included in the meta-
analysis. One study received a D-grade because different
analytical platforms were used to analyze the samples
throughout the study (paper 309). Four were performed in
non-healthy subjects, one in children, two had included
only two samples per subject and one reported a greatly
differing estimate and had been derived with an older
version of the turbidimetric analytical method (paper 285)
(Figure 4). Only the recent EuBIVAS paper 483 received an
A grade [15]. The CVI estimate based on meta-analysis of
4.0% (3.9–8.6%) is slightly lower than that provided in the
historical database (CVI=5.0%) [6]. This is caused by the
exclusion of the eight papers mentioned and the inclusion
of one A-grade paper that had a strong influence on the
new estimate (Figure 4).
Cystatin C clearly demonstrates the challenges of
attempting a meta-analysis for a relatively new analyte
with few studies available for inclusion. The analytical
methods differ greatly (nephelometry, turbidimetry),
and their influence on BV is unknown since it is
possible that they measure different measurands. Given
the increasing importance of this analyte in renal
medicine, further high-quality BV studies for cystatin C
are needed.
Chloride
Critical appraisal with the BIVAC identified only the
recently published EuBIVAS paper as anA paper (335), and
the remaining 26 papers as C. Eight studies fulfilled the
criteria to be included in the meta-analysis, which deliv-
ered a CVI estimate of 1.1%, a little lower than that reported
in the historical database (1.3%) (Table 2) [6].
Estimates derived from studies performed in non-
healthy persons varied, but most showed only slightly
higher estimates than the meta-analysis derived point
estimates for healthy subjects (Figure 5). Data from one
study (168) was a clear outlier on visual inspection of the
data. This was a 1970 study using a Technicon electrometry
chloride analysis on samples obtained from nine healthy
volunteers. Review of the study did not reveal any obvious
reason for the highly increased result [24].
As for age, CVI estimates of 1.3% (1.0–1.5%) and 1.4%
(1.1–1.6%%) for elderly men and women respectively were
reported in paper 246, which did not appear different from
those in non-elderly adults (Table 2).
Potassium and sodium
The estimates for the BV of sodium and potassium in serum
and plasma delivered by this meta-analysis were slightly
lower than those reported by the historical database [6]
(Table 2), although the historical values were within the CI
found in this study.
Based on paper 246, old age (>75 years) did not appear
to influence the CVI of potassium and sodium. Two studies
had assessed BV of these electrolytes in children (248,
270a,b), but the study 248 was a within-day study and
study 270 included only two samples per subject.
Focusing on studies of non-healthy subjects; two pa-
pers (72 and 74) reported data for sodium and potassium
that did not differ from the estimates derived from healthy
individuals. This was, however, not the case for the papers
studying patients with renal transplantation (paper 7),
myocardial infarction (paper 45) and renal disease (paper
46) where higher CVI values than healthy subjects were
observed. These observationswere evident for both sodium
and potassium studies (Figure 5).
Two studies performed in healthy adults reported re-
sults for sodium based on within-day sampling (paper 46;
CVI 2.4%, and 266; CVI 2.2%) that were not within the 95%
CI for the point estimate derived from our meta-analysis
(Table 2). This might be relevant for clinical settings in
which high frequent analysis of electrolytes is performed.
Urea
Within-day studies BVof urea (papers 27, 248), performed in
healthy individuals, demonstrated significant differences in
CVI (4.8 and 7.5%) as compared to the estimates based on
biweekly to monthly samplings (Figure 6). As with creati-
nine, urea is frequently measured in patients with differing
sampling intervals depending on the clinical setting, and
this may need to be taken into account when monitoring
patients. However, standardized studies are required to
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clearly conclude on this issue. The meta-analysis derived
CVI estimate of 13.9% (95%CI; 9.5–14.4) is highly influenced
by the estimate from the EuBIVAS A-graded paper, and this
may be the main reason for the meta-analysis estimates
being slightly higher than the estimate reported in the his-
torical database (median CVI=12%) [6].
Opportunities for additional research
Although Kashani et al. [25] state that there are also other
important biomarkers of acute kidney injuries, such as
neutrophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule (KIM-1), liver-type fatty acid-binding pro-
tein (L-FABP), interleukin 18 (IL-18), insulin-like growth
factor-binding protein 7, tissue inhibitor of metal-
loproteinase 2 (TIMP-2) and calprotectin, they have not
been included in this review because none or only one
study on BV was available for these analytes [18]. All these
markers are candidates for early detection of acute kidney
injury and appropriate BV studies are therefore warranted.
Electrolyte measurements also offer an opportunity for
additional research. Electrolytes are commonly measured in
intensive care settings multiple times per day, often as a
standard part of blood gas analysis. Because of the tight
regulationof sodiumconcentrationwithinonepatient, there is
a risk of interpreting analytical variation as a clinically sig-
nificant change. The only papers that report within-day vari-
ation arrivedat slightly higher estimates for CVI. For sodium in
intensive care unit patients, appropriately powered BIVAC
compliant studies, or studies based on a big data design, are
needed to deliver data on hour-to-hour BV of sodium.
Conclusions
Extensively researched measurands such as the electro-
lytes, creatinine and urea have producedmany paperswith
comparable values for BV components. The recently pub-
lished BIVAC compliant EuBIVAS grade A study has
confirmed the accuracy of these data, and further A studies
do not appear necessary. However, for cystatin C for
instance, more data are required.
Some data indicate that BV estimates may be different in
some groups of non-healthy subjects as compared to the
healthy population. However, proving equality between a
groupofhealthy andnon-healthy subjectsmay require a fully
BIVAC compliant study that directly compares both groups.
There are few studies of BV in children and the
elderly for most of the measurands. This and differing
clinical scenarios are drivers for delivery of appropriately
designed BIVAC compliant BV studies for a range of old
and new measurands; targets should include elderly, chil-
dren, specific disease states, analytes in clinical scenarios
where within day BV and/or long term BV are required,
analytes with few, conflicting or no associated BV data.
Clinicians and Laboratory Medicine Specialists should
recognize BV data as reference data that might vary in
quality and applicability to their local populations and
clinical scenarios. Many BV estimates are the result of well
characterized rigorous studies reproduced by multiple
groups around the world, but many target measurands
appear to require more extensive study. The recent publi-
cation of the new EFLM BV database [9] updated with
newly published studies, combined with the future de-
livery of new studies that appropriately powered and
BIVAC compliant will provide a useful tool for better
healthcare by enabling effective application of appropri-
ately specified laboratory test.
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